Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration

Engin Akyol, Andrew Lotery Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UKCorrespondence: Andrew LoteryClinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton Gene...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Akyol E, Lotery A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	choroidal neovascularisation geographic atrophy gene therapy macular degeneration stem cell therapy monoclonal antibodies Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/662d7e46cea145a9a309137ec7852940
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:662d7e46cea145a9a309137ec7852940
record_format	dspace
spelling	oai:doaj.org-article:662d7e46cea145a9a309137ec78529402021-12-02T12:28:44ZGene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration1177-5491https://doaj.org/article/662d7e46cea145a9a309137ec78529402020-09-01T00:00:00Zhttps://www.dovepress.com/gene-cell-and-antibody-based-therapies-for-the-treatment-of-age-relate-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Engin Akyol, Andrew Lotery Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UKCorrespondence: Andrew LoteryClinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 806, South Lab & Path Block, Tremona Road, Southampton SO16 6YD, UKTel +44 23 8120 5049Email a.j.lotery@soton.ac.ukAbstract: Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated.Keywords: choroidal neovascularisation, geographic atrophy, gene therapy, macular degeneration, stem cell therapy, monoclonal antibodiesAkyol ELotery ADove Medical Pressarticlechoroidal neovascularisationgeographic atrophygene therapymacular degenerationstem cell therapymonoclonal antibodiesMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 83-94 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	choroidal neovascularisation geographic atrophy gene therapy macular degeneration stem cell therapy monoclonal antibodies Medicine (General) R5-920
spellingShingle	choroidal neovascularisation geographic atrophy gene therapy macular degeneration stem cell therapy monoclonal antibodies Medicine (General) R5-920 Akyol E Lotery A Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
description	Engin Akyol, Andrew Lotery Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UKCorrespondence: Andrew LoteryClinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 806, South Lab & Path Block, Tremona Road, Southampton SO16 6YD, UKTel +44 23 8120 5049Email a.j.lotery@soton.ac.ukAbstract: Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated.Keywords: choroidal neovascularisation, geographic atrophy, gene therapy, macular degeneration, stem cell therapy, monoclonal antibodies
format	article
author	Akyol E Lotery A
author_facet	Akyol E Lotery A
author_sort	Akyol E
title	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
title_short	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
title_full	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
title_fullStr	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
title_full_unstemmed	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration
title_sort	gene, cell and antibody-based therapies for the treatment of age-related macular degeneration
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/662d7e46cea145a9a309137ec7852940
work_keys_str_mv	AT akyole genecellandantibodybasedtherapiesforthetreatmentofagerelatedmaculardegeneration AT loterya genecellandantibodybasedtherapiesforthetreatmentofagerelatedmaculardegeneration
_version_	1718394456457084928

Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration

Ejemplares similares